Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Commvault Systems Inc (CVLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Commvault Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Commvault Systems Inc trades at $152.08 (market cap $6.24B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.4× Commvault Systems Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CVLT | |
|---|---|---|
Market Cap | $39.89B | $6.24B |
Sector | Health | Technology |
52-Week High | $491.22 | $195.41 |
52-Week Low | $278.09 | $75.18 |
Enterprise Value | $38.15B | $6.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Commvault (CVLT) trades at $150.57, down 0.57% on the day, with a bullish technical signal from moving averages and strong support at $146. The company reported revenue of $995.62M in 2025, with net income of $76.11M, though earnings have been mixed with two beats and one miss in recent quarters. A high P/E of 95.3 indicates premium valuation, while ROE stands at 42.49%. Recent news highlights a securities class action lawsuit with a July 17, 2026 deadline.
Outlook is mixed: analyst consensus is bullish with 54.55% buy ratings and a $128.75 price target, but legal risks and high valuation pose headwinds. Revenue growth to $1.2B in 2026 offers upside, yet profit margin compression and lawsuit uncertainty require caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →
